請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/81949完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 蔡錦華(Ching-Hwa Tsai) | |
| dc.contributor.author | Han-Yu Tsai | en |
| dc.contributor.author | 蔡函育 | zh_TW |
| dc.date.accessioned | 2022-11-25T03:07:16Z | - |
| dc.date.available | 2026-08-26 | |
| dc.date.copyright | 2021-09-16 | |
| dc.date.issued | 2021 | |
| dc.date.submitted | 2021-08-27 | |
| dc.identifier.citation | Agematsu K, Nagumo H, Shinozaki K, Hokibara S, Yasui K, Terada K, Kawamura N, Toba T, Nonoyama S, Ochs HD et al. 1998. Absence of IgD-CD27(+) memory B cell population in X-linked hyper-IgM syndrome. The Journal of clinical investigation 102: 853-860. Baer R, Bankier AT, Biggin MD, Deininger PL, Farrell PJ, Gibson TJ, Hatfull G, Hudson GS, Satchwell SC, Séguin C et al. 1984. DNA sequence and expression of the B95-8 Epstein—Barr virus genome. Nature 310: 207-211. Banati F, Koroknai A, Salamon D, Takacs M, Minarovits-Kormuta S, Wolf H, Niller HH, Minarovits J. 2008. CpG-methylation silences the activity of the RNA polymerase III transcribed EBER-1 promoter of Epstein-Barr virus. FEBS Letters 582: 705-709. Beatty PR, Krams SM, Martinez OM. 1997. Involvement of IL-10 in the autonomous growth of EBV-transformed B cell lines. The Journal of Immunology 158: 4045. Brisse M, Ly H. 2019. Comparative Structure and Function Analysis of the RIG-I-Like Receptors: RIG-I and MDA5. Frontiers in Immunology 10. Burdin N, Rousset F, Banchereau J. 1997. B-cell-derived IL-10: production and function. Methods 11: 98-111. Burke AP, Yen TS, Shekitka KM, Sobin LH. 1990. Lymphoepithelial carcinoma of the stomach with Epstein-Barr virus demonstrated by polymerase chain reaction. Mod Pathol 3: 377-380. Burkitt D. 1958. A sarcoma involving the jaws in African children. Br J Surg 46: 218-223. -. 1962. A lymphoma syndrome in African children. Ann R Coll Surg Engl 30: 211-219. Chang KL, Chen Y-Y, Shibata D, Weiss LM. 1992. Description of an In Situ Hybridization Methodology for Detection of Epstein-Barr Virus RNA in Paraffin-Embedded Tissues, with a Survey of Normal and Neoplastic Tissues. Diagnostic Molecular Pathology 1. Chiu YH, Macmillan JB, Chen ZJ. 2009. RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. Cell 138: 576-591. Clarke PA, Schwemmle M, Schickinger J, Hilse K, Clemens MJ. 1991. Binding of Epstein-Barr virus small RNA EBER-1 to the double-stranded RNA-activated protein kinase DAI. Nucleic Acids Res 19: 243-248. Countryman J, Miller G. 1985. Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc Natl Acad Sci U S A 82: 4085-4089. Dambaugh T, Beisel C, Hummel M, King W, Fennewald S, Cheung A, Heller M, Raab-Traub N, Kieff E. 1980. Epstein-Barr virus (B95-8) DNA VII: molecular cloning and detailed mapping. Proc Natl Acad Sci U S A 77: 2999-3003. de Waal Malefyt R, Haanen J, Spits H, Roncarolo MG, te Velde A, Figdor C, Johnson K, Kastelein R, Yssel H, de Vries JE. 1991. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 174: 915-924. Dolyniuk M, Pritchett R, Kieff E. 1976. Proteins of Epstein-Barr virus. I. Analysis of the polypeptides of purified enveloped Epstein-Barr virus. J Virol 17: 935-949. Donnelly RP, Dickensheets H, Finbloom DS. 1999. The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes. J Interferon Cytokine Res 19: 563-573. Epstein MA, Achong BG, Barr YM. 1964. VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA. Lancet 1: 702-703. Epstein MA, Barr YM. 1964. CULTIVATION IN VITRO OF HUMAN LYMPHOBLASTS FROM BURKITT'S MALIGNANT LYMPHOMA. Lancet 1: 252-253. Feederle R, Kost M, Baumann M, Janz A, Drouet E, Hammerschmidt W, Delecluse HJ. 2000. The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. Embo j 19: 3080-3089. Feng Q, Langereis MA, Lork M, Nguyen M, Hato SV, Lanke K, Emdad L, Bhoopathi P, Fisher PB, Lloyd RE et al. 2014. Enterovirus 2Apro targets MDA5 and MAVS in infected cells. J Virol 88: 3369-3378. Fiola S, Gosselin D, Takada K, Gosselin J. 2010. TLR9 contributes to the recognition of EBV by primary monocytes and plasmacytoid dendritic cells. J Immunol 185: 3620-3631. Fixman ED, Hayward GS, Hayward SD. 1995. Replication of Epstein-Barr virus oriLyt: lack of a dedicated virally encoded origin-binding protein and dependence on Zta in cotransfection assays. J Virol 69: 2998-3006. Fluckiger AC, Garrone P, Durand I, Galizzi JP, Banchereau J. 1993. Interleukin 10 (IL-10) upregulates functional high affinity IL-2 receptors on normal and leukemic B lymphocytes. J Exp Med 178: 1473-1481. Follenzi A, Santambrogio L, Annoni A. 2007. Immune responses to lentiviral vectors. Curr Gene Ther 7: 306-315. Gack MU, Albrecht RA, Urano T, Inn KS, Huang IC, Carnero E, Farzan M, Inoue S, Jung JU, García-Sastre A. 2009. Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe 5: 439-449. Gack MU, Shin YC, Joo C-H, Urano T, Liang C, Sun L, Takeuchi O, Akira S, Chen Z, Inoue S et al. 2007. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 446: 916-920. Given D, Yee D, Griem K, Kieff E. 1979. DNA of Epstein-Barr virus. V. Direct repeats of the ends of Epstein-Barr virus DNA. Journal of virology 30: 852-862. Go NF, Castle BE, Barrett R, Kastelein R, Dang W, Mosmann TR, Moore KW, Howard M. 1990. Interleukin 10, a novel B cell stimulatory factor: unresponsiveness of X chromosome-linked immunodeficiency B cells. Journal of Experimental Medicine 172: 1625-1631. Goodman SR, Prezyna C, Benz WC. 1978. Two Epstein-Barr virus-associated DNA polymerase activities. J Biol Chem 253: 8617-8628. Goubau D, Schlee M, Deddouche S, Pruijssers AJ, Zillinger T, Goldeck M, Schuberth C, Van der Veen AG, Fujimura T, Rehwinkel J et al. 2014. Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5'-diphosphates. Nature 514: 372-375. Greifenegger N, Jäger M, Kunz-Schughart LA, Wolf H, Schwarzmann F. 1998. Epstein-Barr virus small RNA (EBER) genes: differential regulation during lytic viral replication. J Virol 72: 9323-9328. Hardwick JM, Lieberman PM, Hayward SD. 1988. A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen. J Virol 62: 2274-2284. Hausen HZ, O'Neill FJ, Freese UK, Hecker E. 1978. Persisting oncogenic herpesvirus induced by the tumour promoter TPA. Nature 272: 373-375. Hausen HZ, Schulte-Holthausen H, Klein G, Henle W, Henle G, Clifford P, Santesson L. 1970. Epstein–Barr Virus in Burkitt's Lymphoma and Nasopharyngeal Carcinoma: EBV DNA in Biopsies of Burkitt Tumours and Anaplastic Carcinomas of the Nasopharynx. Nature 228: 1056-1058. Henderson S, Huen D, Rowe M, Dawson C, Johnson G, Rickinson A. 1993. Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. Proc Natl Acad Sci U S A 90: 8479-8483. Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R, Kieff E, Rickinson A. 1991. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 65: 1107-1115. Henle G, Henle W. 1966. Immunofluorescence in cells derived from Burkitt's lymphoma. J Bacteriol 91: 1248-1256. Henle G, Henle W, Diehl V. 1968. Relation of Burkitt #039;s tumor-associated herpes-ytpe virus to infectious mononucleosis. Proceedings of the National Academy of Sciences 59: 94. Hornung V, Ellegast J, Kim S, Brzózka K, Jung A, Kato H, Poeck H, Akira S, Conzelmann KK, Schlee M et al. 2006. 5'-Triphosphate RNA is the ligand for RIG-I. Science 314: 994-997. Hu BT, Insel RA. 1999. Up-regulation of telomerase in human B lymphocytes occurs independently of cellular proliferation and with expression of the telomerase catalytic subunit. Eur J Immunol 29: 3745-3753. Hutt-Fletcher LM. 2007. Epstein-Barr Virus Entry. Journal of Virology 81: 7825. Incrocci R, Barse L, Stone A, Vagvala S, Montesano M, Subramaniam V, Swanson-Mungerson M. 2017. Epstein-Barr Virus Latent Membrane Protein 2A (LMP2A) enhances IL-10 production through the activation of Bruton's tyrosine kinase and STAT3. Virology 500: 96-102. Iwakiri D, Sheen T-S, Chen J-Y, Huang DP, Takada K. 2005. Epstein–Barr virus-encoded small RNA induces insulin-like growth factor 1 and supports growth of nasopharyngeal carcinoma-derived cell lines. Oncogene 24: 1767-1773. Iyer SS, Cheng G. 2012. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Crit Rev Immunol 32: 23-63. Janeway CA, Jr. 1989. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 54 Pt 1: 1-13. Jog NR, Chakravarty EF, Guthridge JM, James JA. 2018. Epstein Barr Virus Interleukin 10 Suppresses Anti-inflammatory Phenotype in Human Monocytes. Frontiers in Immunology 9. Johansson B, Klein G, Henle W, Henle G. 1970. Epstein-Barr virus (EBV)-associated antibody patterns in malignant lymphoma and leukemia. I. Hodgkin's disease. Int J Cancer 6: 450-462. Jones JF, Shurin S, Abramowsky C, Tubbs RR, Sciotto CG, Wahl R, Sands J, Gottman D, Katz BZ, Sklar J. 1988. T-Cell Lymphomas Containing Epstein–Barr Viral DNA in Patients with Chronic Epstein–Barr Virus Infections. New England Journal of Medicine 318: 733-741. Kamesaki H, Fukuhara S, Tatsumi E, Uchino H, Yamabe H, Miwa H, Shirakawa S, Hatanaka M, Honjo T. 1986. Cytochemical, immunologic, chromosomal, and molecular genetic analysis of a novel cell line derived from Hodgkin's disease. Blood 68: 285-292. Kawai T, Takahashi K, Sato S, Coban C, Kumar H, Kato H, Ishii KJ, Takeuchi O, Akira S. 2005. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nature Immunology 6: 981-988. Kikuta H, Taguchi Y, Tomizawa K, Kojima K, Kawamura N, Ishizaka A, Sakiyama Y, Matsumoto S, Imai S, Kinoshita T et al. 1988. Epstein-Barr virus genome-positive T lymphocytes in a boy with chronic active EBV infection associated with Kawasaki-like disease. Nature 333: 455-457. Kitagawa N, Goto M, Kurozumi K, Maruo S, Fukayama M, Naoe T, Yasukawa M, Hino K-i, Suzuki T, Todo S et al. 2000. Epstein–Barr virus-encoded poly(A)− RNA supports Burkitt's lymphoma growth through interleukin-10 induction. The EMBO Journal 19: 6742-6750. Kumar H, Kawai T, Akira S. 2011. Pathogen recognition by the innate immune system. Int Rev Immunol 30: 16-34. Küppers R. 2003. B cells under influence: transformation of B cells by Epstein–Barr virus. Nature Reviews Immunology 3: 801-812. Lambert SL, Martinez OM. 2007. Latent membrane protein 1 of EBV activates phosphatidylinositol 3-kinase to induce production of IL-10. J Immunol 179: 8225-8234. Lee M-A, Diamond ME, Yates JL. 1999. Genetic Evidence that EBNA-1 Is Needed for Efficient, Stable Latent Infection by Epstein-Barr Virus. Journal of Virology 73: 2974. Lerner MR, Andrews NC, Miller G, Steitz JA. 1981. Two small RNAs encoded by Epstein-Barr virus and complexed with protein are precipitated by antibodies from patients with systemic lupus erythematosus. Proceedings of the National Academy of Sciences of the United States of America 78: 805-809. Levy Y, Brouet JC. 1994. Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. J Clin Invest 93: 424-428. Li Q, Spriggs MK, Kovats S, Turk SM, Comeau MR, Nepom B, Hutt-Fletcher LM. 1997. Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes. Journal of virology 71: 4657-4662. Liu B-S, Cao Y, Huizinga TW, Hafler DA, Toes REM. 2014. TLR-mediated STAT3 and ERK activation controls IL-10 secretion by human B cells. European Journal of Immunology 44: 2121-2129. Liu M, Zhao X, Ma Y, Zhou Y, Deng M, Ma Y. 2018. Transcription factor c-Maf is essential for IL-10 gene expression in B cells. Scandinavian Journal of Immunology 88: e12701. Liu S, Chen J, Cai X, Wu J, Chen X, Wu YT, Sun L, Chen ZJ. 2013. MAVS recruits multiple ubiquitin E3 ligases to activate antiviral signaling cascades. Elife 2: e00785. Liu Y, de Waal Malefyt R, Briere F, Parham C, Bridon JM, Banchereau J, Moore KW, Xu J. 1997. The EBV IL-10 homologue is a selective agonist with impaired binding to the IL-10 receptor. The Journal of Immunology 158: 604. Longnecker RM, Kieff E, Cohen JI. 2013. Epstein-barr virus. in Fields Virology: Sixth Edition. Luka J, Kallin B, Klein G. 1979. Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate. Virology 94: 228-231. Maharaj NP, Wies E, Stoll A, Gack MU. 2012. Conventional protein kinase C-α (PKC-α) and PKC-β negatively regulate RIG-I antiviral signal transduction. Journal of virology 86: 1358-1371. Mahot S, Sergeant A, Drouet E, Gruffat H. 2003. A novel function for the Epstein–Barr virus transcription factor EB1/Zta: induction of transcription of the hIL-10 gene. Journal of General Virology 84: 965-974. Maloy KJ, Powrie F. 2001. Regulatory T cells in the control of immune pathology. Nat Immunol 2: 816-822. Martinez OM, Krams SM. 2017. The Immune Response to Epstein Barr Virus and Implications for Posttransplant Lymphoproliferative Disorder. Transplantation 101: 2009-2016. Meng Z, Lu M. 2017. RNA Interference-Induced Innate Immunity, Off-Target Effect, or Immune Adjuvant? Frontiers in immunology 8: 331-331. Miller G, Lipman M. 1973. Release of infectious Epstein-Barr virus by transformed marmoset leukocytes. Proceedings of the National Academy of Sciences of the United States of America 70: 190-194. Miyazawa M, Noguchi K, Kujirai M, Katayama K, Yamagoe S, Sugimoto Y. 2018. IL-10 promoter transactivation by the viral K-RTA protein involves the host-cell transcription factors, specificity proteins 1 and 3. Journal of Biological Chemistry 293: 662-676. Moore KW. 1990. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRF. 1 Science 248: 1230. Moore KW, Vieira P, Fiorentino DF, Trounstine ML, Khan TA, Mosmann TR. 1990. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science 248: 1230-1234. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. 1986. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136: 2348-2357. Muti G, Klersy C, Baldanti F, Granata S, Oreste P, Pezzetti L, Gatti M, Gargantini L, Caramella M, Mancini V et al. 2003. Epstein-Barr virus (EBV) load and interleukin-10 in EBV-positive and EBV-negative post-transplant lymphoproliferative disorders. Br J Haematol 122: 927-933. Nalesnik MA. 1998. Clinical and pathological features of post-transplant lymphoproliferative disorders (PTLD). Springer Seminars in Immunopathology 20: 325-342. Nanbo A, Inoue K, Adachi-Takasawa K, Takada K. 2002. Epstein-Barr virus RNA confers resistance to interferon-alpha-induced apoptosis in Burkitt's lymphoma. Embo j 21: 954-965. Nemerow GR, Mold C, Schwend VK, Tollefson V, Cooper NR. 1987. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d. J Virol 61: 1416-1420. Niller HH, Salamon D, Ilg K, Koroknai A, Banati F, Bauml G, Rucker O, Schwarzmann F, Wolf H, Minarovits J. 2003. The in vivo binding site for oncoprotein c-Myc in the promoter for Epstein-Barr virus (EBV) encoding RNA (EBER) 1 suggests a specific role for EBV in lymphomagenesis. Med Sci Monit 9: Hy1-9. Nomoto A, Detjen B, Pozzatti R, Wimmer E. 1977. The location of the polio genome protein in viral RNAs and its implication for RNA synthesis. Nature 268: 208-213. O'Garra A, Vieira P. 2007. TH1 cells control themselves by producing interleukin-10. Nature Reviews Immunology 7: 425-428. Oshiumi H, Matsumoto M, Hatakeyama S, Seya T. 2009. Riplet/RNF135, a RING Finger Protein, Ubiquitinates RIG-I to Promote Interferon-β Induction during the Early Phase of Viral Infection*. Journal of Biological Chemistry 284: 807-817. Oshiumi H, Miyashita M, Matsumoto M, Seya T. 2013. A distinct role of Riplet-mediated K63-Linked polyubiquitination of the RIG-I repressor domain in human antiviral innate immune responses. PLoS Pathog 9: e1003533. Oyama T, Ichimura K, Suzuki R, Suzumiya J, Ohshima K, Yatabe Y, Yokoi T, Kojima M, Kamiya Y, Taji H et al. 2003. Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients. Am J Surg Pathol 27: 16-26. Palm NW, Medzhitov R. 2009. Pattern recognition receptors and control of adaptive immunity. Immunol Rev 227: 221-233. Peisley A, Lin C, Wu B, Orme-Johnson M, Liu M, Walz T, Hur S. 2011. Cooperative assembly and dynamic disassembly of MDA5 filaments for viral dsRNA recognition. Proceedings of the National Academy of Sciences 108: 21010. Quan H, Kim J, Na YR, Kim JH, Kim BJ, Kim BJ, Hong JJ, Hwang ES, Seok SH. 2020. Human Cytomegalovirus-Induced Interleukin-10 Production Promotes the Proliferation of Mycobacterium massiliense in Macrophages. Front Immunol 11: 518605. Reikine S, Nguyen JB, Modis Y. 2014. Pattern Recognition and Signaling Mechanisms of RIG-I and MDA5. Frontiers in Immunology 5. Rodriguez KR, Bruns AM, Horvath CM. 2014. MDA5 and LGP2: accomplices and antagonists of antiviral signal transduction. J Virol 88: 8194-8200. Rosa MD, Gottlieb E, Lerner MR, Steitz JA. 1981. Striking similarities are exhibited by two small Epstein-Barr virus-encoded ribonucleic acids and the adenovirus-associated ribonucleic acids VAI and VAII. Mol Cell Biol 1: 785-796. Saitoh T, Tun-Kyi A, Ryo A, Yamamoto M, Finn G, Fujita T, Akira S, Yamamoto N, Lu KP, Yamaoka S. 2006. Negative regulation of interferon-regulatory factor 3–dependent innate antiviral response by the prolyl isomerase Pin1. Nature Immunology 7: 598-605. Samanta M, Iwakiri D, Kanda T, Imaizumi T, Takada K. 2006. EB virus-encoded RNAs are recognized by RIG-I and activate signaling to induce type I IFN. Embo j 25: 4207-4214. Samanta M, Iwakiri D, Takada K. 2008. Epstein–Barr virus-encoded small RNA induces IL-10 through RIG-I-mediated IRF-3 signaling. Oncogene 27: 4150-4160. Samanta M, Takada K. 2010. Modulation of innate immunity system by Epstein-Barr virus-encoded non-coding RNA and oncogenesis. Cancer Sci 101: 29-35. Sambrook J. 2001. Molecular cloning : a laboratory manual / Joseph Sambrook, David W. Russell. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. Saraiva M, Christensen JR, Tsytsykova AV, Goldfeld AE, Ley SC, Kioussis D, O'Garra A. 2005. Identification of a macrophage-specific chromatin signature in the IL-10 locus. J Immunol 175: 1041-1046. Saraiva M, O'Garra A. 2010. The regulation of IL-10 production by immune cells. Nature Reviews Immunology 10: 170-181. Satoh T, Kato H, Kumagai Y, Yoneyama M, Sato S, Matsushita K, Tsujimura T, Fujita T, Akira S, Takeuchi O. 2010. LGP2 is a positive regulator of RIG-I– and MDA5-mediated antiviral responses. Proceedings of the National Academy of Sciences 107: 1512. Schmidt A, Schwerd T, Hamm W, Hellmuth JC, Cui S, Wenzel M, Hoffmann FS, Michallet M-C, Besch R, Hopfner K-P et al. 2009. 5′-triphosphate RNA requires base-paired structures to activate antiviral signaling via RIG-I. Proceedings of the National Academy of Sciences 106: 12067. Schuberth-Wagner C, Ludwig J, Bruder AK, Herzner AM, Zillinger T, Goldeck M, Schmidt T, Schmid-Burgk JL, Kerber R, Wolter S et al. 2015. A Conserved Histidine in the RNA Sensor RIG-I Controls Immune Tolerance to N1-2'O-Methylated Self RNA. Immunity 43: 41-51. Stoecklin G, Tenenbaum SA, Mayo T, Chittur SV, George AD, Baroni TE, Blackshear PJ, Anderson P. 2008. Genome-wide analysis identifies interleukin-10 mRNA as target of tristetraprolin. J Biol Chem 283: 11689-11699. Sun Z, Ren H, Liu Y, Teeling JL, Gu J. 2011. Phosphorylation of RIG-I by casein kinase II inhibits its antiviral response. J Virol 85: 1036-1047. Swaminathan S, Hesselton R, Sullivan J, Kieff E. 1993. Epstein-Barr virus recombinants with specifically mutated BCRF1 genes. Journal of Virology 67: 7406-7413. Takada K. 1984. Cross-linking of cell surface immunoglobulins induces Epstein-Barr virus in Burkitt lymphoma lines. Int J Cancer 33: 27-32. Takashima K, Oshiumi H, Takaki H, Matsumoto M, Seya T. 2015. RIOK3-mediated phosphorylation of MDA5 interferes with its assembly and attenuates the innate immune response. Cell Rep 11: 192-200. Takeuchi O, Akira S. 2010. Pattern Recognition Receptors and Inflammation. Cell 140: 805-820. Thorley-Lawson DA, Allday MJ. 2008. The curious case of the tumour virus: 50 years of Burkitt's lymphoma. Nature Reviews Microbiology 6: 913-924. Thorley-Lawson DA, Gross A. 2004. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 350: 1328-1337. Tsai WS, Chang MH, Chen JY, Lee CY, Liu YG. 1989. Seroepidemiological study of Epstein-Barr virus infection in children in Taipei. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi 30: 81-86. Vieira P, de Waal-Malefyt R, Dang MN, Johnson KE, Kastelein R, Fiorentino DF, deVries JE, Roncarolo MG, Mosmann TR, Moore KW. 1991. Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. Proceedings of the National Academy of Sciences 88: 1172. Vockerodt M, Haier B, Buttgereit P, Tesch H, Kube D. 2001. The Epstein-Barr virus latent membrane protein 1 induces interleukin-10 in Burkitt's lymphoma cells but not in Hodgkin's cells involving the p38/SAPK2 pathway. Virology 280: 183-198. Wang JT, Doong SL, Teng SC, Lee CP, Tsai CH, Chen MR. 2009. Epstein-Barr virus BGLF4 kinase suppresses the interferon regulatory factor 3 signaling pathway. J Virol 83: 1856-1869. Wang S, Wang K, Lin R, Zheng C. 2013. Herpes simplex virus 1 serine/threonine kinase US3 hyperphosphorylates IRF3 and inhibits beta interferon production. Journal of virology 87: 12814-12827. Wu Y, Maruo S, Yajima M, Kanda T, Takada K. 2007. Epstein-Barr Virus (EBV)-Encoded RNA 2 (EBER2) but Not EBER1 Plays a Critical Role in EBV-Induced B-Cell Growth Transformation. Journal of Virology 81: 11236. Xu C, Sun L, Liu W, Duan Z. 2018. Latent Membrane Protein 1 of Epstein-Barr Virus Promotes RIG-I Degradation Mediated by Proteasome Pathway. Front Immunol 9: 1446. Yang L, Aozasa K, Oshimi K, Takada K. 2004. Epstein-Barr Virus (EBV)-Encoded RNA Promotes Growth of EBV-Infected T Cells through Interleukin-9 Induction. Cancer Research 64: 5332. Yang M, Sun L, Wang S, Ko KH, Xu H, Zheng BJ, Cao X, Lu L. 2010. Novel function of B cell-activating factor in the induction of IL-10-producing regulatory B cells. J Immunol 184: 3321-3325. Yates JL, Warren N, Sugden B. 1985. Stable replication of plasmids derived from Epstein–Barr virus in various mammalian cells. Nature 313: 812-815. Yoneyama M, Kikuchi M, Matsumoto K, Imaizumi T, Miyagishi M, Taira K, Foy E, Loo YM, Gale M, Jr., Akira S et al. 2005. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J Immunol 175: 2851-2858. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, Taira K, Akira S, Fujita T. 2004. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 5: 730-737. Young LS, Rickinson AB. 2004. Epstein-Barr virus: 40 years on. Nat Rev Cancer 4: 757-768. Zeidler R, Eissner Gn, Meissner P, Uebel S, Tampé R, Lazis S, Hammerschmidt W. 1997. Downregulation of TAP1 in B Lymphocytes by Cellular and Epstein-Barr Virus–Encoded Interleukin-10. Blood 90: 2390-2397. Zeng Y, Middeldorp J, Madjar JJ, Ooka T. 1997. A major DNA binding protein encoded by BALF2 open reading frame of Epstein-Barr virus (EBV) forms a complex with other EBV DNA-binding proteins: DNAase, EA-D, and DNA polymerase. Virology 239: 285-295. Zhao J, Zeng Y, Xu S, Chen J, Shen G, Yu C, Knipe D, Yuan W, Peng J, Xu W et al. 2016. A Viral Deamidase Targets the Helicase Domain of RIG-I to Block RNA-Induced Activation. Cell Host Microbe 20: 770-784. Zhao W. 2013. Negative regulation of TBK1-mediated antiviral immunity. FEBS Lett 587: 542-548. Zheng X, Wang J, Wei L, Peng Q, Gao Y, Fu Y, Lu Y, Qin Z, Zhang X, Lu J et al. 2018. Epstein-Barr Virus MicroRNA miR-BART5-3p Inhibits p53 Expression. Journal of virology 92: e01022-01018. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/81949 | - |
| dc.description.abstract | "EB病毒 (Epstein-Barr virus, EBV) 隸屬於人類皰疹病毒科 (Herpesviridae) 中的γ皰疹病毒亞科，並且是第一個被定義與人類腫瘤密切相關的病毒。其感染與多種人類惡性腫瘤及淋巴細胞增生疾病具高度相關性，包含鼻咽癌 (nasopharyngeal carcinoma, NPC)、巴氏淋巴瘤 (Burkitt’s lymphoma)、霍杰金氏症 (Hodgkin’s disease) 及移植後淋巴組織增生症 (post-transplant lymphoproliferative disease, PTLD) 等。在體外，EB病毒感染人類B淋巴球細胞後，使其不朽化成具持續增生能力之類淋巴母芽細胞株 (lymphoblastoid cell line, LCL)。 EB病毒為了潛伏於B淋巴球細胞中，會調控許多宿主基因的表現以躲避免疫系統的攻擊。實驗室先前利用cDNA微陣列及細胞激素微陣列分析B淋巴球細胞在EB病毒感染後基因表現及細胞激素變化情形，其中IL-10的表現在EB病毒感染後顯著上升。已知IL-10具有抗發炎反應及促進B淋巴球細胞生長的特性，並且移植病人血清中IL-10表現的提高可作為EB病毒相關之PTLD早期指標，顯示IL-10對於EB病毒相關之PTLD的發生亦扮演重要的角色。本研究欲於PTLD體外模型LCL中探討EB病毒感染B淋巴球細胞後誘導IL-10表現之機制。 在先前的報導中，Dr. Takada等人根據於Akata細胞株之實驗結果提出EBERs經由RIG-I及其下游IRF3誘導IL-10表現之假說。本研究欲探討辨識dsRNA的Retinoic acid-inducible gene-I-like receptors (RLRs) 在LCL中對於IL-10表現之影響，實驗結果發現EB病毒的感染雖不影響RIG-I的表現，但能促進MDA5的表達。進一步以shRNA分別降解RIG-I或MDA5 mRNA後，LCL中IL-10的基因轉錄有下降的趨勢，並且皆能抑制下游訊息傳遞分子TBK1的活化，顯示RIG-I及MDA5的存在對於LCL中IL-10的表現皆是重要的，並可能透過活化下游訊息傳遞路徑促進IL-10之表現。 欲釐清RIG-I及MDA5之活化並誘導IL-10的表現是否由EBERs所引起，在不帶有EB病毒之人類霍杰金氏症細胞株KMH2中轉導EBER1或EBER2皆能促進IL10基因的轉錄，並且於LCL中剔除EBERs基因的表達可抑制IL-10的表現，由此確認了EBERs誘發IL10基因表現的能力。然而，在KMH2表現EBER1及EBER2或是於LCL中剔除EBERs基因的表達對TBK1及IRF3的影響皆不明顯，在本次的實驗中未能證實EBERs誘導IL-10表現之分子機制，EBERs是否為LCL中造成RLRs活化並誘導IL-10表現之分子仍待釐清。 綜合以上實驗結果，本研究發現RIG-I及MDA5對於LCL中IL10基因的表達都是重要的，EB病毒的感染可以誘導MDA5的表現或活化RLRs下游訊息傳遞而可能促進IL-10的表現 ; 另外，我們再次驗證EBERs促進IL-10表現的能力，然而其是否為誘發LCL中RLRs活化以促進IL-10表現之分子仍需要更多驗證。" | zh_TW |
| dc.description.provenance | Made available in DSpace on 2022-11-25T03:07:16Z (GMT). No. of bitstreams: 1 U0001-2408202113272900.pdf: 8680384 bytes, checksum: 2de68eb9aafe5facdb8b16d10d15ec87 (MD5) Previous issue date: 2021 | en |
| dc.description.tableofcontents | 口試審定書………………………………………………………...………………….. ..I 致謝……………………………………………………………………………………...II 中文摘要…………………………………………………………………………III 英文摘要…………………………………………………………………………V 第一章 序論………………………………………………………………………1 EB病毒………………………………………………………………………...1 EB病毒小RNA……………………………………………………………….6 模式識別受體………………………………………………………………….9 白血球介素-10………………………………………………………………..13 實驗目的……………………………………………………………………...18 第二章 材料與方法………………………………………………………………19 實驗材料……………………………………………………………………...19 實驗方法……………………………………………………………………...24 第三章 實驗結果……………………………………...………………………………34 EB病毒感染初代B淋巴球細胞後IL-10之表現情形…………………….34 探討RIG-I對LCL中IL-10表現之影響…………………………….……..34 B淋巴球細胞與LCL中RIG-I表現情形…………………………………..35 探討LCL中RIG-I對下游訊息傳遞之影響………………….…………….36 探討MDA5對LCL中IL-10表現之影響………………………………….36 B淋巴球細胞與LCL中MDA5表現情形…………………………………37 探討LCL中MDA5對下游訊息傳遞之影響……………….………...……37 探討EB病毒小RNA EBERs對IL-10表現之影響……….……………….38 探討EBERs對RLRs下游訊息傳遞活化情形…………………….……….39 第四章 討論………………………………………………………………………40 第五章 圖表………………………………………………………………………44 第六章 附錄………………………………………………………………………64 第七章 參考文獻…………………………………………………………………74 | |
| dc.language.iso | zh-TW | |
| dc.subject | IL-10 | zh_TW |
| dc.subject | EBERs | zh_TW |
| dc.subject | MDA5 | zh_TW |
| dc.subject | RIG-I | zh_TW |
| dc.subject | EB病毒 | zh_TW |
| dc.subject | MDA5 | en |
| dc.subject | EBV | en |
| dc.subject | EBERs | en |
| dc.subject | RIG-I | en |
| dc.subject | IL-10 | en |
| dc.title | 探討EB病毒產物在不朽化之類淋巴母芽細胞株中透過RLRs路徑對IL-10表現之影響 | zh_TW |
| dc.title | The effects of Epstein-Barr virus products on IL-10 expression through RLRs signaling pathway in lymphoblastoid cell lines | en |
| dc.date.schoolyear | 109-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 顧家綺(Hsin-Tsai Liu),呂仁(Chih-Yang Tseng) | |
| dc.subject.keyword | EB病毒,EBERs,RIG-I,MDA5,IL-10, | zh_TW |
| dc.subject.keyword | EBV,EBERs,RIG-I,MDA5,IL-10, | en |
| dc.relation.page | 89 | |
| dc.identifier.doi | 10.6342/NTU202102668 | |
| dc.rights.note | 同意授權(全球公開) | |
| dc.date.accepted | 2021-08-27 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 微生物學研究所 | zh_TW |
| dc.date.embargo-lift | 2026-08-26 | - |
| 顯示於系所單位： | 微生物學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| U0001-2408202113272900.pdf 此日期後於網路公開 2026-08-26 | 8.48 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。